 |
인쇄하기
취소
|
AstraZeneca Korea opposes price reduction of Iressa
AstraZeneca Korea filed comments against the government's demand of price readjustment on the cancer drug Iressa (genfitinib) following a civic group's petition last March.
In its petition, the Health World Network argued that the insurance price of Iressa is higher than that prevailing in foreign countries in terms of the U.S.'s FSS (Federal Supply Schedule) price.
In its response, Astra...
In its petition, the Health World Network argued that the insurance price of Iressa is higher than that prevailing in foreign countries in terms of the U.S.'s FSS (Federal Supply Schedule) price.
In its response, Astra...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.